Theriva Biologics, Inc.
TOVX
$0.25
$0.00-0.28%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 300.00K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 300.00K | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 300.00K | -- | -- | -- |
| SG&A Expenses | 2.03M | 2.07M | 1.71M | 1.26M | 1.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.30M | 2.43M | 2.84M | 3.81M | 3.93M |
| Operating Income | -3.30M | -2.13M | -2.84M | -3.81M | -3.93M |
| Income Before Tax | -3.22M | -2.04M | -2.00M | -4.36M | -13.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.22M | -2.04M | -2.00M | -4.36M | -13.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.22M | -2.04M | -2.00M | -4.36M | -13.06M |
| EBIT | -3.30M | -2.13M | -2.84M | -3.81M | -3.93M |
| EBITDA | -3.27M | -2.10M | -2.81M | -3.78M | -3.91M |
| EPS Basic | -0.07 | -0.05 | -0.12 | -0.45 | -1.93 |
| Normalized Basic EPS | -0.04 | -0.03 | -0.06 | -0.24 | -0.36 |
| EPS Diluted | -0.07 | -0.05 | -0.12 | -0.45 | -1.93 |
| Normalized Diluted EPS | -0.04 | -0.03 | -0.06 | -0.24 | -0.36 |
| Average Basic Shares Outstanding | 45.89M | 41.07M | 29.28M | 9.68M | 6.75M |
| Average Diluted Shares Outstanding | 45.89M | 41.07M | 29.28M | 9.68M | 6.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |